Financial Reports
Related Searches:
Filter by:
April 29, 2009
Revenues would have risen 2%, were it not for the impact of a strengthening dollar.
Read More »
April 28, 2009
U.S. revenues were $5.0 billion (-10%) and International revenues were $5.9 billion (-7%). Foreign exchange unfavorably impacted revenues by approximately 5%.
Read More »
April 28, 2009
Biopharmaceutical sales totaled $4.3 billion in the quarter, with U.S. sales up 13% to $2.8 billion and International sales down 11% to $1.5 billion (+2% excluding foreign exchange impact).
Read More »
April 28, 2009
Global Specialty Injectables revenue was down 7.5% to 429.7 million, with Europe, Middle East & Africa sales down 26% to $57.6 million and the Americas down 2% to $333.1 million.
Read More »
April 24, 2009
Total product sales were down 8% to $3.2 billion, partly reflecting the negative impact of foreign exchange. Sales in the U.S. were $2.5 billion (-10%).
Read More »
April 23, 2009
Product sales were up 27% to a record $1.5 billion driven by the antiviral franchise, with sales up 28% to $1.3 billion.
Read More »
April 23, 2009
Biopharmaceutical business revenue was up 28% driven by Tysabri sales, offsetting reduced sales of Azactam and Maxipime.
Read More »
April 22, 2009
Pharmaceutical product sales in the quarter were $8.1 billion (-15%). Seretide/Advair sales were $1.7 billion (-11%).
Read More »
April 22, 2009
Development segment revenue was $335.4 million (-7%). Discovery sciences segment revenue was $5.7 million (-64%).
Read More »
April 22, 2009
Myozyme sales were flat at $67.4 million. In February, the company received EU approval of Myozyme produced at the 4000 L scale.
Read More »
April 21, 2009
Worldwide sales of Singulair were $1.1 billion (-4%). Combined global sales of Zetia and Vytorin, as reported by the Merck/Schering-Plough partnership, were $945 million (-23%).
Read More »
April 21, 2009
Pharmaceutical sales were down 5% to $3.4 billion, reflecting operational growth of 5% and an unfavorable impact from foreign exchange of 10%. Sales of Remicade were $518 million (+2%).
Read More »
April 20, 2009
Zyprexa sales were flat at $1.1 billion; Cymbalta sales were $709.3 million (+17%); Humalog sales were up 11% to $450.6 million; Gemzar sales were $367.8 million (-14%).
Read More »
April 17, 2009
Growth was driven by Tysabri sales up 44% to $165 million, Rituxan sales through the company's partnership with Genentech were up 13% to $279 million, and Avonex sales were up 4% to $555 million.
Read More »
April 16, 2009
Pharmaceutical revenues were flat at $8.1 billion (up 8% in local currencies) with Europe/ROW sales down 8%, U.S. sales up 1%, and Japan sales up 58%.
Read More »
